rethinkPeptides Search
Menu
Study breakdown

Smoking Disrupts Pain-Regulating Peptides in Fibromyalgia, Making Pain Worse

evidence
The takeaway

Women with fibromyalgia who smoke have lower leptin and a missing neuropeptide Y response, which correlates with significantly worse pain.

NPY-pain threshold correlation: rho = 0.414

Higher neuropeptide Y levels were directly linked to better pain tolerance — but smokers with fibromyalgia failed to produce the expected NPY increase

What the researchers found

In 62 women with fibromyalgia, current smokers (n=18) had significantly lower leptin levels than ex-smokers (n=25, P=0.002). Normally, smoking stimulates neuropeptide Y (NPY) production through nicotinic receptors, but this expected NPY increase was absent in fibromyalgia patients. Without that compensatory NPY response, smokers with fibromyalgia experienced worse outcomes: higher pain scores on VAS (P=0.04), more tender points (P=0.03), and lower pain thresholds (P=0.01). NPY levels directly correlated with pain threshold (rho=0.414) and inversely correlated with tender point counts (rho=-0.375). The findings suggest that a broken leptin-NPY feedback loop may be a key mechanism underlying chronic pain in fibromyalgia.

Why it matters

Fibromyalgia's pain mechanisms remain poorly understood, which makes effective treatment difficult. This study identifies a specific peptide imbalance — the failure of neuropeptide Y to rise in response to low leptin — that may help explain why some fibromyalgia patients experience more severe pain. It also shows that smoking, which many patients may use as self-medication, actually worsens pain outcomes in this population through peptide dysregulation.

The numbers in context

n=62 women · 18 current smokers · 25 ex-smokers · Leptin lower in smokers P=0.002 · VAS-pain higher P=0.04 · Tender points higher P=0.03 · Pain threshold lower P=0.01 · NPY-pain threshold rho=0.414

How the study worked

Cross-sectional study of 62 women with fibromyalgia. Pain was assessed using a visual analogue scale (VAS), tender point counts, and pressure pain thresholds. Neuroendocrine markers (NPY, substance P) and adipokines (leptin, IGF-1, resistin, visfatin, adiponectin) were measured in blood and cerebrospinal fluid. Patients were grouped by smoking status: current smokers, ex-smokers, and never-smokers.

Who was studied

62 women with fibromyalgia (18 current smokers, 25 ex-smokers)

What this study cannot tell us

Small sample of 62 women, limiting statistical power for subgroup analyses. Cross-sectional design cannot establish causation — it's unclear whether peptide dysregulation causes worse pain or results from it. All-female cohort limits generalizability to men with fibromyalgia. Self-reported smoking status may be unreliable.

How to read the evidence

Small cross-sectional clinical study with 62 patients. Provides interesting correlational data and a plausible mechanism, but cannot prove causation. Small subgroups limit the strength of between-group comparisons.

When this study was published

Published in 2014 in Mediators of Inflammation. The role of neuropeptides in fibromyalgia pain remains an active research area, and the leptin-NPY connection identified here continues to be explored.

The bigger picture

Fibromyalgia affects an estimated 2-4% of the global population, yet its underlying mechanisms remain elusive. This study points to a specific peptide pathway — the leptin-NPY axis — as a contributor to chronic pain in these patients. It connects metabolic signaling (adipokines like leptin) to pain processing (neuropeptides like NPY), suggesting that fibromyalgia may involve disrupted communication between the body's energy and pain regulation systems. This could eventually inform peptide-based therapeutic approaches.

Questions still open

  • Could restoring NPY levels therapeutically reduce pain in fibromyalgia patients?
  • Is the leptin-NPY dysregulation specific to fibromyalgia, or present in other chronic pain conditions?
  • Does smoking cessation reverse the peptide imbalance and improve pain outcomes in these patients?

Common questions

What is neuropeptide Y and how does it affect pain?
Neuropeptide Y (NPY) is a peptide produced in the brain and nervous system that helps regulate pain sensitivity, stress responses, and appetite. Higher NPY levels are associated with better pain tolerance. In this study, fibromyalgia patients who smoked failed to produce the normal NPY increase, which correlated with worse pain.
Does smoking make fibromyalgia worse?
According to this study, yes. Smokers with fibromyalgia had significantly higher pain scores, more tender points, and lower pain thresholds than ex-smokers. The researchers found this was linked to disrupted leptin and neuropeptide Y levels — peptides that normally help regulate pain — suggesting a biological mechanism beyond lifestyle factors.

Read the original research

Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia.

Mediators of inflammation, 2014, 627041

Citation

Bokarewa, Maria I; Erlandsson, Malin C; Bjersing, Jan; Dehlin, Mats; Mannerkorpi, Kaisa. (2014). Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia.. Mediators of inflammation, 2014, 627041. https://doi.org/10.1155/2014/627041